Bearish flow noted in Sarepta (SRPT) with 2,510 puts trading, or 1.9x expected. Most active are Jan-27 20 puts and Jan-26 30 puts, with total ...

After a challenging year for Sarepta Therapeutics, its chief executive has received his first equity grant in about eight ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.

Investing.com -- Sarepta Therapeutics Inc (NASDAQ:SRPT) stock fell 3.7% on Thursday after the company announced a debt exchange agreement that will restructure a portion of its convertible notes.

Investing.com -- Sarepta Therapeutics (NASDAQ:SRPT) stock fell 8% on Thursday after the rare disease medicine specialist announced it would refinance approximately $291 million of its convertible ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...

Wondering if Sarepta Therapeutics is a beaten down biotech bargain or a value trap? This article will walk through the numbers in plain English so you can decide with confidence. Despite a brutal long ...

Fintel reports that on December 9, 2025, Wedbush initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Outperform recommendation. Analyst Price Forecast Suggests 37.06% Upside As of ...

On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...